Hughes Arlene R, Brothers Cynthia H, Mosteller Michael, Spreen William R, Burns Daniel K
GlaxoSmithKline Genetics, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, USA.
Pharmacogenomics. 2009 Feb;10(2):225-33. doi: 10.2217/14622416.10.2.225.
Abacavir hypersensitivity (ABC HSR) is a treatment-limiting adverse event associated with the use of the antiretroviral medicine, abacavir. The objective of the ABC HSR pharmacogenetics program was to identify clinically useful genetic risk factors to predict an individual patient's risk for ABC HSR. The major histocompatibility complex allele, HLA-B5701, was identified retrospectively and confirmed with independent sample sets. The clinical utility of prospective HLA-B5701 screening was demonstrated in a blinded randomized clinical trial and in open-label cohorts. Screening has been incorporated into clinical practice and the ABC HSR pharmacogenetics program has been highlighted as a success by pharmacogenetics researchers. Important lessons from this pharmacogenetics program will be discussed in this paper.
阿巴卡韦超敏反应（ABC HSR）是一种与使用抗逆转录病毒药物阿巴卡韦相关的限制治疗的不良事件。ABC HSR药物遗传学项目的目标是识别临床上有用的遗传风险因素，以预测个体患者发生ABC HSR的风险。主要组织相容性复合体等位基因HLA - B5701通过回顾性研究得以识别，并在独立样本集中得到证实。前瞻性HLA - B5701筛查的临床实用性在一项双盲随机临床试验和开放标签队列研究中得到了证明。筛查已被纳入临床实践，ABC HSR药物遗传学项目也被药物遗传学研究人员视为一项成功案例。本文将讨论该药物遗传学项目的重要经验教训。
